Achieve Life Sciences Inc Asset Resilience Ratio
Achieve Life Sciences Inc asset resilience ratio. Achieve Life Sciences Inc (ACHV) has an Asset Resilience Ratio of 3.60% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Achieve Life Sciences Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Achieve Life Sciences Inc (1996–2025)
Asset resilience ratio of Achieve Life Sciences Inc from 1996 to 2025. This chart shows how Achieve Life Sciences Inc's Asset Resilience Ratio has changed over time. Read Achieve Life Sciences Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Achieve Life Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACHV current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.19 Million | 3.6% |
| Total Liquid Assets | $1.19 Million | 3.60% |
Asset Resilience Insights
- Limited Liquidity: Achieve Life Sciences Inc maintains only 3.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Achieve Life Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Achieve Life Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
Achieve Life Sciences Inc Asset Resilience Ratio by Year (1996–2025)
Achieve Life Sciences Inc asset resilience ratio by year from 1996 to 2025. The table below shows the annual Asset Resilience Ratio data for Achieve Life Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.03% | $15.47 Million | $41.79 Million | -18.90pp |
| 2024-12-31 | 55.93% | $21.61 Million | $38.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $19.37 Million | -- |
| 2019-12-31 | 0.24% | $50.00K | $21.08 Million | -26.43pp |
| 2018-12-31 | 26.67% | $5.09 Million | $19.08 Million | +24.42pp |
| 2017-12-31 | 2.24% | $222.00K | $9.89 Million | -35.00pp |
| 2016-12-31 | 37.24% | $10.23 Million | $27.47 Million | +1.38pp |
| 2015-12-31 | 35.86% | $20.88 Million | $58.21 Million | +1.83pp |
| 2014-12-31 | 34.04% | $19.16 Million | $56.29 Million | -10.19pp |
| 2013-12-31 | 44.23% | $24.63 Million | $55.69 Million | -25.65pp |
| 2012-12-31 | 69.87% | $57.31 Million | $82.02 Million | +16.34pp |
| 2011-12-31 | 53.53% | $36.41 Million | $68.02 Million | -14.95pp |
| 2010-12-31 | 68.48% | $61.57 Million | $89.92 Million | +64.83pp |
| 2009-12-31 | 3.65% | $2.52 Million | $68.98 Million | -36.18pp |
| 2008-12-31 | 39.83% | $5.89 Million | $14.79 Million | -21.30pp |
| 2007-12-31 | 61.14% | $27.66 Million | $45.25 Million | +28.28pp |
| 2006-12-31 | 32.86% | $22.51 Million | $68.49 Million | -56.48pp |
| 2004-12-31 | 89.34% | $20.16 Million | $22.57 Million | +5.70pp |
| 2003-12-31 | 83.63% | $17.95 Million | $21.47 Million | -5.34pp |
| 2002-12-31 | 88.97% | $15.96 Million | $17.93 Million | -3.50pp |
| 2001-12-31 | 92.47% | $14.67 Million | $15.86 Million | +45.19pp |
| 2000-12-31 | 47.28% | $6.77 Million | $14.31 Million | -13.00pp |
| 1999-12-31 | 60.28% | $10.91 Million | $18.10 Million | -6.48pp |
| 1996-12-31 | 66.75% | $17.89 Million | $26.80 Million | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more